Thinh Ngoc Tran
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Thinh Ngoc Tran has a total of 231 co-authors. Here are the top co-authors by number of shared publications:
- Nikolaus Schultz
Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center
49 shared publications - Hira Rizvi
Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York
43 shared publications - Matthew D. Hellmann
Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York
43 shared publications - Justin Jee
Computational Oncology Service, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, USA
40 shared publications - Gregory J. Riely
Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY
39 shared publications - Ino de Bruijn
Memorial Sloan Kettering Cancer Center
39 shared publications
Latest Publications
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Fig. 2 from The GENIE BPC NSCLC Cohort: A Real-World Repository Integrating Standardized Clinical and Genomic Data for 1,846 Patients with Non–Small Cell Lung Cancer
Supplemental Figure 2: OS and PFS for patients with NSCLC treated with first-line platinum-based chemotherapy.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Fig. 2 from The GENIE BPC NSCLC Cohort: A Real-World Repository Integrating Standardized Clinical and Genomic Data for 1,846 Patients with Non–Small Cell Lung Cancer
Supplemental Figure 2: OS and PFS for patients with NSCLC treated with first-line platinum-based chemotherapy.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Fig. 3 from The GENIE BPC NSCLC Cohort: A Real-World Repository Integrating Standardized Clinical and Genomic Data for 1,846 Patients with Non–Small Cell Lung Cancer
Supplemental Figure 3: PFS estimates for patients with NSCLC treated with standard first- and second-line therapies.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Fig. 3 from The GENIE BPC NSCLC Cohort: A Real-World Repository Integrating Standardized Clinical and Genomic Data for 1,846 Patients with Non–Small Cell Lung Cancer
Supplemental Figure 3: PFS estimates for patients with NSCLC treated with standard first- and second-line therapies.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Fig. 1 from The GENIE BPC NSCLC Cohort: A Real-World Repository Integrating Standardized Clinical and Genomic Data for 1,846 Patients with Non–Small Cell Lung Cancer
Supplemental Figure 1: OS and PFS for KRAS-mutated NSCLC treated with first-line platinum-based chemotherapy.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Fig. 1 from The GENIE BPC NSCLC Cohort: A Real-World Repository Integrating Standardized Clinical and Genomic Data for 1,846 Patients with Non–Small Cell Lung Cancer
Supplemental Figure 1: OS and PFS for KRAS-mutated NSCLC treated with first-line platinum-based chemotherapy.
- Open Access
- 26 September 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-10
AI cancer driver mutation predictions are valid in real-world data
Characterizing and validating which mutations influence development of cancer is challenging. Artificial intelligence (AI) has delivered significant advances in protein structure prediction, but its utility for identifying cancer drivers is less explored. We evaluate multiple computational methods for identifying cancer driver mutations. For re-identifying known drivers, methods incorporating protein structure or functional genomic data outperform methods trained only on evolutionary data. We validate variants of unknown significance (VUSs) annotated as pathogenic by testing their association with overall survival in two cohorts of patients with non-small cell lung cancer (N = 7965 and 977). VUSs identified as pathogenic drivers by AI in KEAP1 and SMARCA4 are associated with worse survival, unlike “benign” VUSs. “Pathogenic” VUSs also exhibit mutual exclusivity with known oncogenic alterations at the pathway level, further suggesting biological validity. AI predictions thus contribute to a more comprehensive understanding of tumor genetics as validated by real-world data.
- 26 September 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-10
Open AccessAI cancer driver mutation predictions are valid in real-world data
Characterizing and validating which mutations influence development of cancer is challenging. Artificial intelligence (AI) has delivered significant advances in protein structure prediction, but its utility for identifying cancer drivers is less explored. We evaluate multiple computational methods for identifying cancer driver mutations. For re-identifying known drivers, methods incorporating protein structure or functional genomic data outperform methods trained only on evolutionary data. We validate variants of unknown significance (VUSs) annotated as pathogenic by testing their association with overall survival in two cohorts of patients with non-small cell lung cancer (N = 7965 and 977). VUSs identified as pathogenic drivers by AI in KEAP1 and SMARCA4 are associated with worse survival, unlike “benign” VUSs. “Pathogenic” VUSs also exhibit mutual exclusivity with known oncogenic alterations at the pathway level, further suggesting biological validity. AI predictions thus contribute to a more comprehensive understanding of tumor genetics as validated by real-world data.
- Top Cited PapersOpen Access
- 6 November 2024
- Published by Springer Nature in Nature
- Vol. 636 (8043) , 728-736
Automated real-world data integration improves cancer outcome prediction
The digitization of health records and growing availability of tumour DNA sequencing provide an opportunity to study the determinants of cancer outcomes with unprecedented richness. Patient data are often stored in unstructured text and siloed datasets. Here we combine natural language processing annotations1,2 with structured medication, patient-reported demographic, tumour registry and tumour genomic data from 24,950 patients at Memorial Sloan Kettering Cancer Center to generate a clinicogenomic, harmonized oncologic real-world dataset (MSK-CHORD). MSK-CHORD includes data for non-small-cell lung (n = 7,809), breast (n = 5,368), colorectal (n = 5,543), prostate (n = 3,211) and pancreatic (n = 3,109) cancers and enables discovery of clinicogenomic relationships not apparent in smaller datasets. Leveraging MSK-CHORD to train machine learning models to predict overall survival, we find that models including features derived from natural language processing, such as sites of disease, outperform those based on genomic data or stage alone as tested by cross-validation and an external, multi-institution dataset. By annotating 705,241 radiology reports, MSK-CHORD also uncovers predictors of metastasis to specific organ sites, including a relationship between SETD2 mutation and lower metastatic potential in immunotherapy-treated lung adenocarcinoma corroborated in independent datasets. We demonstrate the feasibility of automated annotation from unstructured notes and its utility in predicting patient outcomes. The resulting data are provided as a public resource for real-world oncologic research.
- 6 November 2024
- Published by Springer Nature in Nature
- Vol. 636 (8043) , 728-736
Top Cited PapersOpen AccessAutomated real-world data integration improves cancer outcome prediction
The digitization of health records and growing availability of tumour DNA sequencing provide an opportunity to study the determinants of cancer outcomes with unprecedented richness. Patient data are often stored in unstructured text and siloed datasets. Here we combine natural language processing annotations1,2 with structured medication, patient-reported demographic, tumour registry and tumour genomic data from 24,950 patients at Memorial Sloan Kettering Cancer Center to generate a clinicogenomic, harmonized oncologic real-world dataset (MSK-CHORD). MSK-CHORD includes data for non-small-cell lung (n = 7,809), breast (n = 5,368), colorectal (n = 5,543), prostate (n = 3,211) and pancreatic (n = 3,109) cancers and enables discovery of clinicogenomic relationships not apparent in smaller datasets. Leveraging MSK-CHORD to train machine learning models to predict overall survival, we find that models including features derived from natural language processing, such as sites of disease, outperform those based on genomic data or stage alone as tested by cross-validation and an external, multi-institution dataset. By annotating 705,241 radiology reports, MSK-CHORD also uncovers predictors of metastasis to specific organ sites, including a relationship between SETD2 mutation and lower metastatic potential in immunotherapy-treated lung adenocarcinoma corroborated in independent datasets. We demonstrate the feasibility of automated annotation from unstructured notes and its utility in predicting patient outcomes. The resulting data are provided as a public resource for real-world oncologic research.
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Supplemental Fig. 2 from The GENIE BPC NSCLC cohort: a real-world repository integrating standardized clinical and genomic data for 1,846 patients with non-small cell lung cancer
Supplemental Figure 2: OS and PFS for patients with NSCLC treated with first-line platinum-based chemotherapy.
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Fig. 2 from The GENIE BPC NSCLC cohort: a real-world repository integrating standardized clinical and genomic data for 1,846 patients with non-small cell lung cancer
Supplemental Figure 2: OS and PFS for patients with NSCLC treated with first-line platinum-based chemotherapy.